Corbus Pharmaceuticals Reports Significant Improvement in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
72
Corbus Pharmaceuticals Reports Significant Improvement in mRSS and Other Clinical Outcomes at 28-Weeks in Systemic Sclerosis Open-Label Extension of Phase 2 Study

NORWOOD, MA --(Marketwired - November 06, 2017) -

  • Systemic sclerosis is a rare autoimmune disease with no approved therapies, affecting 90,000 individuals in US and EU with a 10-year mortality rate of 35-50%
  • Anabasum achieved reduction in mRSS of 8.4 points from start of study (p < 0.0001, 2-side paired t-test) exceeding clinically important improvement (-4.7 points)
  • 75% of subjects achieved degree of improvement in mRSS correlated with improved survival
  • Clinical benefit supported by improvement in multiple secondary outcomes and a continued favorable safety profile
  • Company on track to commence Phase 3 study Q4 2017

Corbus Pharmaceuticals Holdings, Inc. ( NASDAQ : CRBP ) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, yesterday presented 6-month safety and efficacy data from the open-label extension ("OLE") dosing in its ongoing Phase 2 study of anabasum ("JBT101-SSc-001") in subjects with diffuse cutaneous systemic sclerosis ("SSc"). The results were presented at the American College of Rheumatology ("ACR") Annual Meeting in San Diego, CA in a poster entitled: "Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in an Open-Label Extension of Trial JBT101-SSc-001. " To access the poster click here .

Anabasum demonstrated a significant and clinically meaningful reduction in mRSS reaching minus 8.4 (p < 0.0001 2-paired t-test) and an ACR CRISS of 71% at 28 weeks OLE. These responses exceeded those seen in the 12-week double-blind placebo-controlled dosing and increased at each visit with 33% of subjects achieving low mRSS scores (≤ 10 points) and 44% achieving a high ACR CRISS > 70%.

Barbara White, M.D., Chief Medical Officer of the Company stated, "The consistency and magnitude of efficacy seen with longer dosing increases our confidence that anabasum could offer a meaningful benefit to patients with SSc. The speed and degree of improvement in multiple efficacy outcomes at this stage in the open-label extension of our Phase 2 study exceeds that previously reported in other clinical trials or registries in SSc."

"Keeping in mind the caveats of an open-label extension study, this level of improvement in this relatively short interval is impressive in the context of data from previous clinical studies in SSc," commented Principal Investigator Robert Spiera, M.D., Director of the Vasculitis and Scleroderma Program at the Hospital for Special Surgery, Weill Cornell Medical College in New York City. "Particularly striking was the loss of the measured CRISS response, our primary outcome in the Phase 2 study, when patients were off medication prior to enrolling in open label extension, with that response again captured when they resumed anabasum. This improvement comes with very manageable safety risks, including no significant changes in laboratory safety test results. I look forward to leading the Phase 3 study."

"These safety and efficacy data are very encouraging and reinforce the positive findings in the double-blinded placebo-controlled part of the study," added Yuval Cohen, Ph.D., Chief Executive Officer of Corbus . "Systemic sclerosis is a very challenging disease and no SSc-specific drugs have been approved by the FDA. Our focus now is to ensure the successful execution of our Phase 3 study, and we are on track to commence this before year end."

Study Design

Thirty-six subjects with diffuse cutaneous SSc received open-label dosing with anabasum at 20 mg twice per day following 16-weeks participation in the preceding double-blinded placebo-controlled part of the anabasum Phase 2 study. Anabasum treatment was in addition to standard-of-care treatments for SSc, including stable doses of concomitant immunosuppressive drugs in 92% of subjects.

Efficacy Outcomes

The modified Rodnan Skin Score (mRSS), the primary outcome for the upcoming Phase 3 study of anabasum in SSc, improved by a mean of -8.4 points (p < 0.0001) from baseline at the start of the Phase 2 double blind placebo controlled portion of the study. The baseline mRSS at study start was 24 points. 75% of subjects achieved a degree of improvement in mRSS (reduction ≥ 5 points and > 25% baseline) that has been associated with improved survival in SSc. A third of subjects reached a low mRSS ≤ 10 points.

The ACR Composite Response Index in diffuse cutaneous Systemic Sclerosis score (ACR CRISS) increased steadily with anabasum treatment and reached 71% (median) from study start with 44% of subjects achieving a score > 70%. The magnitude of this change is more than double what has been observed in analyses of data from clinical studies with other therapeutics. Patient-reported disability, function, skin symptoms and global health all improved from study start and OLE start. Forced vital capacity (FVC) % predicted was stable during anabasum treatment (mean change 0.3% predicted from study start) in contrast to the natural history of a decline in FVC in the disease.

Safety

There were no severe or serious adverse events (AEs) and no clinically significant laboratory abnormalities related to the drug. Thirty (83%) subjects experienced adverse events (AEs) and only 3 (8%) subjects experienced AEs related to anabasum during open-label dosing. The AEs experienced by ≥ 10% of subjects were upper respiratory tract illness in 7 (19%) subjects and urinary tract infection in 5 (14%) subjects.

Anabasum has been granted Orphan Drug Designation and Fast Track status for the treatment of systemic sclerosis from the FDA and Orphan Designation from the EMA.

About Systemic Sclerosis

Systemic sclerosis is a rare and serious systemic autoimmune rheumatic disease with an unclear etiology. Systemic sclerosis affects approximately 90,000 people in the United States and Europe, with disease onset typically in mid-life. About 80 percent of SSc patients are women. The disease process in systemic sclerosis includes activation of the immune system, with damage to small blood vessels and fibrosis of the skin on internal organs, including lungs, heart, kidneys, gastrointestinal tract and musculoskeletal system. Chronic disease burden, morbidity and mortality are significant. Ten-year mortality rates are high at about 35-50%. Cardiopulmonary disease is the major cause of death in SSc. Immunosuppressive medications such as oral corticosteroids, mycophenolate, methotrexate and cyclophosphamide are used to treat patients with more severe signs and symptoms of disease. Currently, there are no FDA-approved treatments specifically indicated for the treatment of systemic sclerosis, other than pulmonary artery hypertension secondary to connective tissue diseases such as systemic sclerosis.

About Anabasum

Anabasum is a synthetic oral endocannabinoid-mimetic drug that preferentially binds to cannabinoid receptor type 2 (CB2) expressed on activated immune cells and fibroblasts. CB2 activation triggers physiologic pathways that resolve inflammation, speed bacterial clearance and halt fibrosis. Nonclinical and human clinical studies to date have shown anabasum has favorable safety, tolerability and pharmacokinetic profiles. It has also demonstrated promising potency in nonclinical models of inflammation and fibrosis. Anabasum is designed to trigger the production of "Specialized Pro-resolving Lipid Mediators" that activate an endogenous cascade responsible for the resolution of inflammation and fibrosis, while reducing production of multiple inflammatory mediators. Anabasum also is designed to have a direct effect on fibroblasts to halt tissue scarring. In effect, anabasum is believed to trigger endogenous pathways to turn "off" chronic inflammation and fibrotic processes without causing immunosuppression.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has generated positive data in Phase 2 studies in diffuse cutaneous systemic sclerosis, cystic fibrosis and dermatomyositis. Additionally, the Company is evaluating anabasum in open-label extension studies in systemic sclerosis and skin-predominant dermatomyositis. The Company expects to commence a Phase 2 study in systemic lupus erythematosus, a Phase 3 study in systemic sclerosis and a Phase 2b study in cystic fibrosis in the fourth quarter of 2017.

For more information, please visit www.CorbusPharma.com and connect with the Company on Twitter , LinkedIn , Google+ and Facebook .

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contacts Jenene Thomas Jenene Thomas Communications, LLC Phone: (908) 938-1475 Email: jenene@jenenethomascommunications.com Media Contact Nic DiBella JPA Health Communications Phone: (617) 657-1307 Email: Nic@jpa.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 102

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading
Workers Are Burning Savings as Pay Falls Behind Costs

Updated Category News Views 69

Payroll optimism has been ground into dust by the ordinary bills nobody can dodge. Monster's 2026 Cost of Living Report says 93% of employed U.S. workers feel their wages are failing to keep up with costs, barely different from 95% in both 2024 and 2025. That is not a blip, and it is not workers merely grousing about prices. Three years of nearly identical frustration...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 108

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 109

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 109

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
KONST Pitches Asia GPU Uptime as AI Demand Gets Real

Updated Category News Views 115

GPU racks are easy to admire when the lights are on; keeping them useful at 3 a.m. is where the bruises show. KONST arrived at SC26 in Chicago with a sensible pitch for an AI-infrastructure market that is getting less impressed by shiny hardware lists and more obsessed with whether the thing actually works. Its theme, “24/7 GPUs Delivered in Asia,” puts the emphasis...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 97

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading
PayPal's New Leadership Map Puts Execution on Trial

Updated Category News Views 106

Four senior appointments and a risk-chief exit can turn a tidy strategy slide into a very real operating test. PayPal has spent months defining three-year plans, simplifying its operating model and assigning clearer accountability; on November 20, it put names beside the jobs. For NASDAQ:PYPL investors, that is more consequential than another broad promise about...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading

Top 5 Most Recently Viewed Articles

Ready Capital Corporation's 2024 Results Overview & Future Insights

Updated Category News Views 176

Ready Capital Corporation's Upcoming Financial Results Ready Capital Corporation (NASDAQ: RC) is poised to share its financial results for the fourth quarter and the full year of 2024. This significant announcement is expected to take place before the opening bell of the New York Stock Exchange on the designated release date. Investors and interested parties are eagerly...

Continue Reading
Nano-X Faces Securities Suit, Investors Alerted

Updated Category News Views 32

Legal Tsunami Hits Nano-X Imaging If there’s one thing that makes investors' hairs stand on end, it’s the words 'class action lawsuit.' And now, it's swirling around Nano-X Imaging Ltd. (NASDAQ: NNOX) like a tempest. The DJS Law Group has taken the lead, lighting the legal torches on claims that Nano-X fed investors a cocktail of misleading statements regarding its...

Continue Reading
Novo Nordisk A/S Shareholders: Take Action on Recent Allegations

Updated Category News Views 218

Understanding the Novo Nordisk A/S Class Action Opportunity Recent developments have led to significant scrutiny of Novo Nordisk A/S, a major player in the pharmaceutical industry. For shareholders, this highlights a crucial opportunity to engage in a class action lawsuit regarding alleged misleading statements about the company's CagriSema weight loss study results....

Continue Reading
Investors of Inspire Medical Systems Should Act Before Deadline

Updated Category News Views 288

Important Deadline for Inspire Medical Systems Investors Investors of Inspire Medical Systems, Inc. are reminded that a critical deadline is approaching for those who purchased securities. The firm Kirby McInerney LLP has encouraged investors to take action as they seek the lead plaintiff role in a federal securities class action. About the Legal Proceedings This lawsuit...

Continue Reading
Nicholas Wealth's Impressive $GIAX Distribution Yield Announcement

Updated Category News Views 88

Recent Announcement from Nicholas Wealth Management Nicholas Wealth, renowned for its commitment to delivering actively managed income ETFs, has made an exciting announcement regarding its latest distribution. The Nicholas Global Equity and Income ETF (GIAX) will offer investors a substantial monthly distribution yield of an impressive 24.00%. This announcement is...

Continue Reading